Compare Ascendis Pharma A/S (ASND) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Upwork Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Upwork Inc trades at $8.89 (market cap $1.09B). The key difference: Ascendis Pharma A/S is far larger — about 16.3× Upwork Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UPWK | |
|---|---|---|
Market Cap | $17.74B | $1.09B |
Sector | Health | Industrials |
52-Week High | $277.18 | $22.11 |
52-Week Low | $163.32 | $7.84 |
Enterprise Value | $18.11B | $890.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UPWK trades at $8.82, up 1.61% today, but faces a bearish technical signal with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. The company reported 2025 revenue of $787.78M with a net income margin of 13.81%, while valuation metrics like a P/E of 10.9 and P/S of 1.55 appear reasonable. However, multiple law firms are investigating potential securities fraud, contributing to negative sentiment after a 19% stock drop post-Q1 2026 results.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but risks include ongoing legal probes, earnings volatility, and competitive pressures in the gig economy. Upside depends on execution improvements and AI integration initiatives like the Upwork Claude Connector announced in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
